olivLaw · European equity research
Genus PLC GNS.L
United Kingdom · London Stock Exchange · ISIN GB0002074580 · Vertical: Listed companies from United Kingdom
Genus PLC is an animal genetics group that helps farmers produce pork and milk more efficiently and sustainably. In fiscal 2026 porcine volumes grew by 12%, to 249.6 million MPEs, while the company works to commercialise its PRP gene-edited pig, which is progressing through approvals in several markets.
At the close of 05 Nov 2026, Genus PLC (GNS.L) stock was 23.90 GBP (+0.00% on the day), with market capitalisation 1.6 bn GBP, P/E 5.6 on diluted EPS of 4.25 GBP over the last 12 months, dividend yield 1.37%, beta 0.86, 52-week range 19.66–31.70 GBP.
Data as of · AI analysis dated · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 62.1
- strong (55–70)
- Bollinger (20, 2)
- 21.96 – 24.20
- in the upper half of the band · %B 0.86 · band width 9.7%
- SMA 50 / 200
- 22.40 / 24.21
- mixed trend
- MACD (12, 26, 9)
- 0.46 / 0.36
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | +13.1% | −0.6% | +13.7 pp | — |
| 3 months | +3.8% | −4.2% | +8.0 pp | — |
| 6 months | +1.4% | +4.3% | −2.9 pp | — |
| Year to date | −7.9% | +7.5% | −15.4 pp | — |
| 1 year | −3.2% | +9.9% | −13.2 pp | +5.8% |
| 3 years | +8.4% | +49.8% | −41.4 pp | +26.3% |
| 5 years | −56.5% | +42.8% | −99.3 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 33 percentile of its own 3-quarter history (min 5.1, median 70.8, max 138.7; quarters with earnings only).
Fiscal years
| Fiscal year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 668.8 m | 672.8 m | 658.1 m |
| Revenue YoY | unavailable | +0.6% | −2.2% |
| Net income | 7.9 m | 19.3 m | 285.3 m |
| Net income YoY | unavailable | +144.3% | +1,378.2% |
| Diluted EPS | 0.12 | 0.29 | 4.25 |
| Diluted EPS YoY | unavailable | +142.9% | +1,370.9% |
| net % | 1.2% | 2.9% | 43.4% |
| Free cash flow | 15.0 m | 53.8 m | 61.9 m |
Balance sheet & financial health
Fiscal year 2026 · 30 Jun 2026
- Cash
- 43.7 m GBP
- Financial debt
- 81.3 m GBP
- Net debt
- 37.6 m GBP
- Equity
- 766.7 m GBP
- Total assets
- 1.0 bn GBP
- Debt / equity
- 0.11x
- Current ratio
- 2.22x
- ROE
- 45.9%
- ROA
- 29.8%
- FCF margin
- 9.4%
Financial statements (source on every figure)
Revenue and net income (GBP)
Margins
Income statement · GBP
| Line | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 668.8 m | 672.8 m | 658.1 m | esef· 15 Oct 2026verified |
| Operating income | 6.4 m | 42.4 m | 87.3 m | esef· 15 Oct 2026verified |
| Interest expense | 22.2 m | 21.4 m | 16.7 m | esef· 15 Oct 2026verified |
| Pre-tax income | 5.5 m | 28.5 m | 310.5 m | esef· 15 Oct 2026verified |
| Income tax | 3.1 m | 9.2 m | 25.0 m | esef· 15 Oct 2026verified |
| Net income | 7.9 m | 19.3 m | 285.3 m | esef· 15 Oct 2026verified |
| Diluted EPS | 0.12 | 0.29 | 4.25 | esef· 15 Oct 2026verified |
| Dividend per share | 0.32 | 0.32 | 0.33 | esef· 15 Oct 2026derived |
Balance sheet · GBP
| Line | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|
| Cash | 42.5 m | 48.0 m | 43.7 m | esef· 15 Oct 2026verified |
| Receivables | 135.2 m | 119.2 m | 120.9 m | esef· 15 Oct 2026verified |
| Inventories | 57.1 m | 46.2 m | 47.8 m | esef· 15 Oct 2026verified |
| Current assets | 271.1 m | 254.4 m | 259.6 m | esef· 15 Oct 2026verified |
| Property, plant & equipment, net | 182.0 m | 160.3 m | — | esef· 21 Oct 2025verified |
| Goodwill | 110.3 m | 102.8 m | 103.4 m | esef· 15 Oct 2026verified |
| Intangibles (excl. goodwill) | 65.4 m | 55.3 m | 49.5 m | esef· 15 Oct 2026verified |
| Total assets | 987.8 m | 899.0 m | 1.0 bn | esef· 15 Oct 2026verified |
| Accounts payable | 123.2 m | 107.7 m | 95.6 m | esef· 15 Oct 2026verified |
| Short-term debt | 4.9 m | 2.9 m | 4.3 m | esef· 15 Oct 2026verified |
| Long-term debt | 228.2 m | 215.9 m | 77.0 m | esef· 15 Oct 2026verified |
| Current liabilities | 150.6 m | 131.3 m | 117.2 m | esef· 15 Oct 2026verified |
| Total liabilities | 474.3 m | 423.0 m | 251.6 m | esef· 15 Oct 2026verified |
| Equity | 513.5 m | 476.0 m | 766.7 m | esef· 15 Oct 2026verified |
| Shares outstanding at year end | 65.8 m | 65.9 m | 66.1 m | esef· 15 Oct 2026derived |
Cash flow · GBP
| Line | 2024 | 2025 | 2026 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | 29.8 m | 67.2 m | 74.4 m | esef· 15 Oct 2026verified |
| Capex | 14.8 m | 13.4 m | 12.5 m | esef· 15 Oct 2026verified |
| Free cash flow | 15.0 m ≈ | 53.8 m ≈ | 61.9 m ≈ | esef· 15 Oct 2026derived |
| Investing cash flow | -19.3 m | -13.8 m | 97.8 m | esef· 15 Oct 2026verified |
| Financing cash flow | -2.8 m | -46.6 m | -178.0 m | esef· 15 Oct 2026verified |
| Dividends paid | 21.0 m | 21.1 m | 21.7 m | esef· 15 Oct 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 59 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 1.6 bn GBP
Key indicators
Coverage and freshness
Score by group
- Valuation71
- Balance sheet74
- Returns52
- Quality46
Estimated value range
unavailable — no valuation assumptions for the reporting currency
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
Assumptions (illustrative, editorial)
- Risk-free rate
- 6.5%
- Equity risk premium
- 6.0%
- Beta (default)
- 1.00
- Cost of equity
- 12.5%
- Terminal growth
- 3.0%
Factor scorecard
Neutral profile · Score 59/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 11.1% | 46 (vs peers) | 17% |
| Net margin · Quality | 43.4% | 91 (vs peers) | 10% |
| FCF conversion · Quality | 21.7% | 0 (on a fixed band) | 10% |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 5.2x | 57 (on a fixed band) | 10% |
| Current ratio · Balance sheet | 2.2x | 100 (on a fixed band) | 7% |
| P/E (TTM) · Valuation | 5.6x | 89 (vs peers) | 17% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 3.9% | 49 (on a fixed band) | 13% |
| Shareholder yield (distributions) · Returns | 1.4% | 20 (on a fixed band) | 10% |
| Payout ratio (FCF) · Returns | 35.1% | 100 (on a fixed band) | 7% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet74/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality46/100 · 3/3 factors with a value
- Returns52/100 · 2/2 factors with a value
- Valuation71/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
GENUS PLC (GNS.L). Latest full fiscal year: 2026; data up to 2026-06-30.
Figures computed from the financial statements: revenue 658.1 m GBP in 2026; YoY growth -2.2%; net margin 43.4%; ROE 45.9%.
The estimated value range is 28.77–43.51 GBP per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 36.16 GBP, the price of 23.90 GBP leaves a potential of 51.3% (value / price − 1) and a margin of safety of 33.9% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 59/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: growth. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 43.4%
- Current ratio: 2.2x
- P/E (TTM): 5.6x
- Payout ratio (FCF): 35.1%
- The price is below the estimated value range
What contradicts it
- FCF conversion: 21.7%
- Shareholder yield (distributions): 1.4%
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, EV/EBITDA.
Versus the vertical median
Listed companies from United Kingdom · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| BATS.LBritish American Tobacco P.L.C. | 104.3 bn | 13.5 | 16.5% | 30.3% | −1.0% | +7% / +88% |
| ABF.LAssociated British Foods PLC | 14.7 bn | 14.3 | 9.2% | 5.3% | −3.1% | −5% / −15% |
| 0EV1.LCarnival PLC | 5.5 bn | 4.1 | 46.7% | 13.4% | +6.4% | unavailable / unavailable |
| BAB.LBabcock International Group PLC | 5.1 bn | 24.7 | 34.7% | 4.1% | +7.2% | −10% / +158% |
| AUTO.LAutotrader Group PLC | 4.8 bn | 16.4 | 60.2% | 47.1% | +3.9% | −13% / −23% |
| BBY.LBalfour Beatty PLC | 4.2 bn | 16.3 | 23.2% | 2.8% | +15.2% | +20% / +160% |
| ABDN.LAberdeen Group PLC | 4.1 bn | 10.8 | 8.0% | 28.9% | −2.1% | +11% / +41% |
| BKG.LThe Berkeley Group Holdings PLC | 3.6 bn | 11.3 | 8.8% | 13.4% | −4.2% | −0% / −22% |
| BME.LB&M European Value Retail PLC | 2.9 bn | 17.4 | 21.2% | 2.8% | +3.7% | +68% / −51% |
| AJB.LAj Bell PLC | 2.4 bn | 22.8 | 49.9% | 33.1% | +18.0% | +8% / +128% |
| GNS.LGenus PLC | 1.6 bn | 5.6 | 45.9% | 43.4% | −2.2% | −9% / +21% |
| ASHM.LAshmore Group PLC | 1.4 bn | 13.9 | 13.1% | 71.6% | −0.1% | +28% / +18% |
| BCG.LBaltic Classifieds Group PLC | 1.2 bn | 23.2 | 15.8% | 57.6% | +6.9% | −99% / −99% |
| APN.LApplied Nutrition PLC | 763.6 m | 36.2 | 41.2% | 19.7% | +24.2% | +71% / unavailable |
| BAG.LA.G. Barr P.L.C. | 671.9 m | 14.4 | 14.4% | 10.8% | +4.0% | −7% / +26% |
| ASC.LAsos PLC | 494.5 m | — | -81.3% | -12.0% | −14.7% | +71% / +8% |
| ALFA.LAlfa Financial Software Holdings PLC | 486.8 m | 16.3 | 61.5% | 23.8% | +15.3% | −28% / +10% |
| AML.LAston Martin Lagonda Global Holdings PLC | 344.3 m | — | -93.4% | -39.2% | −20.6% | −45% / −85% |
| APTD.LAptitude Software Group PLC | 111.3 m | 28.5 | 7.2% | 6.2% | −7.3% | −30% / −23% |
| AMGO.LAmigo Holdings PLC | 9.9 m | — | — | — | −81.9% | +325% / +844% |
| ASBE.LAssociated British Engineering PLC | 605.3 k | — | -19.1% | — | unavailable | unavailable / unavailable |
| AMIF.LAmicorp Fs (uk) PLC | 221.6 k | 0.1 | 27.5% | 9.1% | +8.1% | unavailable / unavailable |
| AAF.LAirtel Africa PLC | — | — | 24.1% | 10.6% | +29.5% | −7% / +164% |
| AAL.LAnglo American PLC | — | — | -19.3% | -20.2% | +4.5% | +30% / +76% |
| ACG.LAcg Metals Limited | — | — | -80.3% | -32.0% | +134.8% | +60% / +63% |
1- and 3-year price returns: for GNS.L from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (GBP)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 13.38 Total return -43% · Per year -43% | 23.74 Total return 1% · Per year 1% | 35.86 Total return 52% · Per year 52% |
| 3 years | 11.30 Total return -50% · Per year -21% | 22.71 Total return -1% · Per year -0% | 37.91 Total return 64% · Per year 18% |
| 5 years | 9.54 Total return -56% · Per year -15% | 21.73 Total return -3% · Per year -1% | 40.08 Total return 76% · Per year 12% |
- Exit P/E± 5.68
- Net margin± 3.97
- Annual revenue growth± 3.49
- Annual dilution± 0.33
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Genus PLC is an animal genetics group that helps farmers produce pork and milk more efficiently and sustainably. In fiscal 2026 porcine volumes grew by 12%, to 249.6 million MPEs 1, while the company works to commercialise its PRP gene-edited pig, which is progressing through approvals in several markets 1.
SWOT
Strengths
- The company holds a strong position in porcine genetics and a royalty portfolio that helps stabilise revenue.
- Research and development is supported by advanced genomic data and life cycle assessments.
- The company has obtained regulatory approvals for its PRP pig in several countries.
Weaknesses
- The bovine business was hit by trade restrictions, and volumes in China declined.
- The company depends on several external factors for supply continuity, including animal movement.
- ABS operating margins are still being improved and have not yet reached target levels.
Opportunities
- Growth in Latin America and Southeast Asia could expand genetics sales if market access improves.
- Commercialising the PRP pig could open new market segments if approvals are secured in key countries.
- Sexing and reproductive technologies could create new revenue streams.
Threats
- Geopolitical tensions and tariffs could reduce international trade.
- Animal diseases could restrict the movement of animals and semen.
- Cyber-attacks enabled by artificial intelligence could rise in frequency and impact.
Risks
- Biosecurity and supply continuityhigh
Rising disease across bovine and porcine markets could restrict the movement of animals and semen, affecting sales 1.
- Agricultural market volatilitymedium
Fluctuations in agricultural prices affect customer profitability and demand for the company's products 1.
- PRP approval and consumer acceptancemedium
Failure to secure approvals in key markets or consumer acceptance could delay commercialisation 1.
- Cyber securitymedium
Advances in artificial intelligence could increase the frequency and impact of cyber-attacks on data and systems 1.
- Development in Chinamedium
Failure to develop the China business could affect growth in a key market, particularly after changes in trade policy 1.
Investment thesis
What would need to be true (bull case)
- Market share in China could rise as the company's genetics demonstrate their value through the new joint venture 1.
- PRP approvals in several countries and consumer interest in gene-edited pork could support new revenue 1.
- The VAP efficiency programme has already delivered benefits and could support better margins at ABS 1.
What would break the thesis
What to watch
- Progress of PRP pig approvals in Mexico and Japan2027
- New emissions intensity metric replacing AWIRFY27
- Results and contribution of the China joint venturenext 10-K
- VAP programme progress at ABS and achievement of target marginsFY27 H1
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Genus PLC develops and commercialises genetic material for farm animals, particularly porcine and bovine, through divisions such as PIC and ABS 1. Its model relies on proprietary genetics, royalties and direct sales of animals and semen. The company aims to help farmers obtain more high-quality protein per unit of feed or water 1.
Segments
Market context
Conditions for meat producers were generally positive, but agricultural markets are cyclical and under pressure from trade tariffs and conflicts in Russia-Ukraine and the Middle East 1. Animal diseases such as African Swine Fever can restrict the movement of animals and semen 1.
Rising demand for safe and affordable animal protein supports long-term demand for improved genetics, but feed costs and commodity price volatility could affect the profitability of farmer customers 1.
Trends
- Geopolitical tensions and tradeheadwind
Heightened US-Iran tensions could disrupt global trade flows through the Strait of Hormuz, potentially raising agricultural and oil-derived commodity prices 1.
- Animal diseaseheadwind
Rising disease outbreaks across bovine and porcine markets may affect the movement of animals and semen, with a direct effect on supply continuity 1.
- PRP pig approvalstailwind
Approvals obtained in Argentina, Canada, Uruguay and Peru open commercialisation in Latin America, while approvals in Mexico and Japan remain pending 1.
- Artificial intelligencemixed
Advances in artificial intelligence may increase the frequency and impact of cyber-attacks, while also reshaping the company's ways of working 1.
Competitive position
The source refers to competitors in porcine and bovine genetics without naming them in the available extracts. The company says it demonstrates its advantage by benchmarking against competitors in customers' systems and through life cycle assessments 1.
Competition for elite genetics is intense, and the company seeks to maintain its edge through genomic data and university partnerships 1.
- Porcine and bovine genetics competitors
The source does not name individual competitors in the available text; it refers only to competition for elite genetics 1.
- Local Chinese genetics players
The company formed a local joint venture, suggesting strong local competition in China 1.
- Sexing technology providers
The IntelliGen sexing technology is developed in-house and through partnerships, and competition for new reproductive technologies is flagged as a risk 1.
- Other elite genetics producers
The risk of competition for elite genetics is explicitly noted in the company's report 1.
News & filings
In the press
- Scientists establish new genus of deep-sea 'spaghetti worms'Phys.org · 14 Oct 2026 · EN
- New insect genus and four species named for Taylor Swift and her albumsPhys.org · 09 Sept 2026 · EN
Annual reports (ESEF)
- Annual report 202615 Oct 2026
- Annual report 202521 Oct 2025
Sources
- [1] Annual report, fiscal year ended 2026-06-30 (ESEF) · SEC / Genus PLC · 30 Jun 2026
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.